In the final segment of this roundtable, the panelists discuss the search for novel targets and strategies to improve renal cell carcinoma (RCC) treatment, particularly in the refractory setting. The conversation highlights promising advancements such as LAG-3, updated interleukins, CAR-T therapies, and bispecific antibodies, as well as the challenges of balancing toxicity and efficacy in these approaches. The panelists also discuss the role of novel therapies in both the frontline and refractory settings, emphasizing the need for innovative, curative strategies. Insights from the TiNivo-2 study are explored, particularly its implications for VEGF inhibitor strategies and its impact ...
Advanced Renal Cell Carcinoma
Advertisement
Latest News
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
Drs. Beckermann and Barata explore the implications of the negative findings of the CONTACT-03 trial on clinical practice.
Disease control was achieved in 84.6% of patients, 4.3% reached a complete response, 52% had partial response.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Advertisement
Section Editor
Katy Beckermann, MD, PhDGenitourinary Medical Oncologist | Vanderbilt-Ingram Cancer Center
Advertisement
Get the latest RCC research straight to your inbox.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.